You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 205776


✉ Email this page to a colleague

« Back to Dashboard


NDA 205776 describes RASUVO, which is a drug marketed by Medexus and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the RASUVO profile page.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
Summary for 205776
Tradename:RASUVO
Applicant:Medexus
Ingredient:methotrexate
Patents:1
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 205776
Generic Entry Date for 205776*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205776
Suppliers and Packaging for NDA: 205776
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776 NDA Medexus Pharma Inc. 59137-505 59137-505-01 1 PACKAGE in 1 CARTON (59137-505-01) / .15 mL in 1 PACKAGE (59137-505-00)
RASUVO methotrexate SOLUTION;SUBCUTANEOUS 205776 NDA Medexus Pharma Inc. 59137-505 59137-505-04 4 PACKAGE in 1 CARTON (59137-505-04) / .15 mL in 1 PACKAGE (59137-505-00)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength7.5MG/0.15ML (7.5MG/0.15ML)
Approval Date:Jul 10, 2014TE:RLD:Yes
Patent:⤷  SubscribePatent Expiration:Jun 1, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:SUBCUTANEOUS INJECTION OF METHOTREXATE

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength10MG/0.20ML (10MG/0.20ML)
Approval Date:Jul 10, 2014TE:RLD:Yes
Patent:⤷  SubscribePatent Expiration:Jun 1, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:SUBCUTANEOUS INJECTION OF METHOTREXATE

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength12.5MG/0.25ML (12.5MG/0.25ML)
Approval Date:Jul 10, 2014TE:RLD:Yes
Patent:⤷  SubscribePatent Expiration:Jun 1, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:SUBCUTANEOUS INJECTION OF METHOTREXATE

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.